RTRX Retrophin, Inc.

19.53
+0.32  (1.67%)
Previous Close 19.21
Open 19.35
Price To book 2.35
Market Cap 736.91M
Shares 37,732,000
Volume 798,828
Short Ratio 13.96
Av. Daily Volume 404,103

SEC filingsSee all SEC filings

  1. 8-K - Current report 17515833
  2. CT ORDER - Confidential treatment order 162052773
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161974856
  4. 8-K - Current report 161971745
  5. 8-K - Current report 161925184

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in coming months - as of January 9, 2017.
RE-024
Pantothenate kinase-associated neurodegeneration (PKAN)
Efficacy trial to be initiated 2H 2016
RE-024
Pantothenate kinase-associated neurodegeneration (PKAN)
NDA filing due 2017
Liquid ursodeoxycholic acid (L-UDCA)
Primary biliary cholangitis (PBC)
Approved Mar 18 2015
Cholbam
Rare Bile Acid Synthesis Disorders
Phase 2 top-line data released September 8, 2016. Further data released 19 November, 2016 at the American Society of Nephrology (ASN) Kidney Week.
Sparsentan (DUET)
Focal segmental glomerulosclerosis (FSGS)

Latest News

  1. RETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  2. Retrophin Provides Corporate Update and 2017 Preview
  3. 'Pharma bro' Shkreli suspended from Twitter for harassment
  4. Retrophin Appoints Elizabeth Reed General Counsel
  5. Retrophin Appoints Elizabeth Reed General Counsel
  6. Retrophin to Present at the 35th Annual J.P. Morgan Healthcare Conference
  7. Biotech Stocks to Watch After Senate Drug Report
  8. The Senate just released a massive report on drug pricing — here's what you need to know
  9. JMP Conducts Retrophin Survey To Understand Story
  10. Retrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : December 13, 2016
  11. Is CF Corp (CFCO) A Good Stock To Buy According To Hedge Funds?
  12. ETFs with exposure to Retrophin, Inc. : December 2, 2016
  13. Retrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : December 1, 2016
  14. Retrophin to Present at the BMO Capital Markets Healthcare Conference
  15. Is Retrophin Inc (RTRX) A Good Stock To Buy?
  16. Ligand's Partner Retrophin Provides New Data on Sparsentan
  17. Here's Why Retrophin's DUET Data Pushes Upside To 129%
  18. Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
  19. Retrophin, Inc. :RTRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
  20. Retrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : November 17, 2016

SEC Filings

  1. 8-K - Current report 17515833
  2. CT ORDER - Confidential treatment order 162052773
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161974856
  4. 8-K - Current report 161971745
  5. 8-K - Current report 161925184
  6. CT ORDER - Confidential treatment order 161906063
  7. S-8 - Securities to be offered to employees in employee benefit plans 161881830
  8. 8-K - Current report 161872209
  9. 8-K - Current report 161833932
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161808763